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Motivation
• Network meta-analysis (NMA) lets us 
compare many treatments and assess 
consistency of treatment effects in a 
connected network
• Model based meta-analysis (MBMA) 
incorporates dose and/or time course 
information in a meta-analysis
• We propose a framework to combine both 
– MBNMA
Structure
• Example data
• Dose in NMA
• Dose response models
• MBNMA methodology
• Evidence consistency
Triptans for migraine relief
Outcome: 
proportion of 
patients 
headache free at 
2 hours
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Data based on:
Thorlund (2014), Cephalagia (34) 258-67


Modelling approaches in NMA
• Single dose for each treatment
• Does not use all available information
• “Lump” doses?
• Ignores dose response
• Risk of inconsistency and heterogeneity
• How to interpret?
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Modelling approaches in NMA
• Treat each agent-dose combination as a 
separate treatment?
• Sparse network.  Ignores dose-response

Modelling approaches in NMA
• Treat each treatment dose combination as 
a separate treatment?
• Sparse network.  Ignores dose-response
• Model dose response curve.
Emax models
• Extend NMA framework
• Can model fixed or random effects
Higgins P T et al (1996) Borrowing Strength from External Trials in a Meta-
Analysis Stats. in Medicine 15(24), 2733-2749
Dias, S et al. (2013). Evidence synthesis for decision making 2: a generalized 
linear modeling framework 7 Medical Decision Making  33(5), 607–17.
Model-based NMA
• Apply consistency equation at the level of 
the dose response curve:
• For a 2 arm trial:
• Apply multi-arm correction for >2 arm trials 
(see Dias et al.)
• Can consider other dose-response models
Model fitting
• Models fitted using JAGS 
• Vague priors used throughout
• Model ED50 on log scale
• Assume class effects on Emax and ED50
• ED50 class effect required for parameter 
estimation (requires dose standardisation)
• Emax class effect improved model fit
Plummer (2003). JAGS: A Program for Analysis of Bayesian Graphical Models
Using Gibbs Sampling, Proceedings of the 3rd International Workshop on 
Distributed Statistical Computing (DSC 2003)
Methods
• Compare:
• Lumped NMA
• Split NMA
• Linear model-based NMA
• Emax model-based NMAs
• Emax and ED50 class effect
• Assess goodness of fit using DIC, residual 
deviance and heterogeneity
Results
Model DIC Residual
Deviance
σ
Lumped NMA 330.5 189.0 0.373
Split NMA 325.2 189.6 0.270
182 data points
(0.289 to 0.469)
(0.178 to 0.376)
Results
Model DIC Residual
Deviance
σ
Lumped NMA 330.5 189.0 0.373
Split NMA 325.2 189.6 0.270
Linear MBNMA (w. int) 321.0 188.7 0.274
Emax (ED50 class) 321.8 191.5 0.249
Emax (2x class effects) 318.7 191.9 0.242
182 data points
(0.289 to 0.469)
(0.192 to 0.371)
(0.159 to 0.350)
(0.160 to 0.335)
(0.178 to 0.376)




Comparison to NMA and 
MBMA
• Avoids lumping doses and/or times
• Makes full use of data
• Allows comparisons in absence of direct 
evidence
• Interpretable results
• Consistency equations
• Ensure self consistent estimates
• Direct and indirect evidence may be in conflict
Evidence consistency
• Where direct and indirect evidence exist for a 
contrast:
• Extract direct evidence for the contrast to separate 
network
• Only indirect evidence for contrast remains
• Compare effect estimates for direct and indirect 
evidence
• Need to compare across whole dose range
• Similar idea to node splitting in NMA
20
36
17
16
9
4
6
1
2 5
2
1
1
1
placebo
almo
suma
ele
riza
zolmi
nara
frova
almo
suma
3
20
36
17
16
9
4
6
1
2 5
2
1
1
1
placebo
almo
suma
ele
riza
zolmi
nara
frova
almo
suma
3
Indirect evidenceDirect evidence
Indirect evidenceDirect evidence
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Evidence consistency
• We fit models for direct and indirect evidence 
simultaneously
• Sharing 
• Sharing 50 and ,  and 
• Required since limited direct evidence on some contrasts
• May obscure inconsistency
• Repeat for each loop of evidence
almotriptan, placebo almotriptan, sumatriptan almotriptan, zolmitriptan eletriptan, naratriptan
eletriptan, sumatriptan eletriptan, zolmitriptan naratriptan, rizatriptan placebo, rizatriptan
placebo, sumatriptan placebo, zolmitriptan rizatriptan, sumatriptan rizatriptan, zolmitriptan
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Evidence consistency
• 12 Loops of evidence
• No evidence of inconsistency between direct 
and indirect evidence on any contrast
• Shared class effects may obscure inconsistency 
since common means assumed
• Developing cross-validation type approach to 
avoid estimating model for direct evidence
Discussion and Future work
• Simulation study
• Explore data requirements & model 
performance
• Cross validation for evidence consistency
• Other functional forms of dose response
• Incorporation of dose and time course 
information
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